B · Normal
[The State Food and Drug Administration conditionally approves the marketing of epolidomide hydrochloride capsules] On September 30, the State Food and Drug Administration passed the priority review and approval process and conditionally approved Bristol-Myers Squibb Pharma The Class 1 innovative drug Eppolidomide Hydrochloride Capsules (trade name: Zanfu) applied by EEIG is on the market. The drug combined with daratumumab and dexamethasone is suitable for the treatment of adult patients with multiple myeloma who have received at least first-line treatment (including a proteasome inhibitor and an immunomodulator). The launch of this drug provides patients with new treatment options.
Comments